Toll-like receptor 3 mediates expression of clusterin/apolipoprotein J in vascular smooth muscle cells stimulated with RNA released from necrotic cells

Experimental Cell Research

Volumn 316, Issue 20, 2010, Pages 3489-3500

  Baiersdorfer M ^a   Schwarz, M ^a   Seehafer, K ^a   Lehmann, C ^a   Heit, A ^b   Wagner, H ^b   Kirschning, C J ^c   Koch Brandt, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Clusterin; Double stranded RNA; Necrotic cells; Toll like receptor 3; Vascular smooth muscle cells

Indexed keywords

ADAPTOR PROTEIN; BETA INTERFERON; CLUSTERIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL LYSATE; CELL STIMULATION; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INDUCTION; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; YOLK SAC;

MUS;

EID: 78149414150     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.07.022     Document Type: Article

References (67)

1. Koch-Brandt C., Morgans C. Clusterin: a role in cell survival in the face of apoptosis?. Prog. Mol. Subcell. Biol. 1996, 16:130-149.
2. French L.E., Wohlwend A., Sappino A.P., Tschopp J., Schifferli J.A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 1994, 93:877-884.
3. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 1995, 27:633-645.
4. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 2000, 50:305-315.
5. McLaughlin L., Zhu G., Mistry M., Ley-Ebert C., Stuart W.D., Florio C.J., Groen P.A., Witt S.A., Kimball T.R., Witte D.P., Harmony J.A., Aronow B.J. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 2000, 106:1105-1113.
6. Wehrli P., Charnay Y., Vallet P., Zhu G., Harmony J., Aronow B., Tschopp J., Bouras C., Viard-Leveugle I., French L.E., Giannakopoulos P. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat. Med. 2001, 7:977-979.
7. Imhof A., Charnay Y., Vallet P.G., Aronow B., Kovari E., French L.E., Bouras C., Giannakopoulos P. Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol. Dis. 2006, 22:274-283.
8. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 2000, 25:95-98.
9. Trougakos I.P., Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 2002, 34:1430-1448.
10. Matsuda A., Itoh Y., Koshikawa N., Akizawa T., Yana I., Seiki M. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J. Biol. Chem. 2003, 278:36350-36357.
11. Santilli G., Aronow B.J., Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J. Biol. Chem. 2003, 278:38214-38219.
12. Bartl M.M., Luckenbach T., Bergner O., Ullrich O., Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 2001, 271:130-141.
13. Bach U.C., Baiersdörfer M., Klock G., Cattaruzza M., Post A., Koch-Brandt C. Apoptotic cell debris and phosphatidylserine-containing lipid vesicles induce apolipoprotein J (clusterin) gene expression in vital fibroblasts. Exp. Cell Res. 2001, 265:11-20.
14. Miyata M., Biro S., Kaieda H., Eto H., Orihara K., Kihara T., Obata H., Matsushita N., Matsuyama T., Tei C. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation 2001, 104:1407-1412.
15. Ishikawa Y., Akasaka Y., Ishii T., Komiyama K., Masuda S., Asuwa N., Choi-Miura N.H., Tomita M. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol. 1998, 18:665-672.
16. Jordan-Starck T.C., Lund S.D., Witte D.P., Aronow B.J., Ley C.A., Stuart W.D., Swertfeger D.K., Clayton L.R., Sells S.F., Paigen B., Harmony J.A.K. Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J. Lipid Res. 1994, 35:194-210.
17. Witte D.P., Aronow B.J., Stauderman M.L., Stuart W.D., Clay M.A., Gruppo R.A., Jenkins S.H., Harmony J.A. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am. J. Pathol. 1993, 143:763-773.
18. Gelissen I.C., Hochgrebe T., Wilson M.R., Easterbrook-Smith S.B., Jessup W., Dean R.T., Brown A.J. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?. Biochem. J. 1998, 331:231-237.
19. Thomas-Salgar S., Millis A.J.T. Clusterin expression in differentiating smooth muscle cells. J. Biol. Chem. 1994, 269:17879-17885.
20. Moulson C.L., Millis A.J.T. Clusterin (apo J) regulates vascular smooth muscle cell differentiation in vitro. J. Cell. Physiol. 1999, 180:355-364.
21. Millis A.J., Luciani M., McCue H.M., Rosenberg M.E., Moulson C.L. Clusterin regulates vascular smooth muscle cell nodule formation and migration. J. Cell. Physiol. 2001, 186:210-219.
22. Sivamurthy N., Stone D.H., Logerfo F.W., Quist W.C. Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells. J. Vasc. Surg. 2001, 34:716-723.
23. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
24. Beutler B., Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 2003, 3:169-176.
25. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335-376.
26. Kawai T., Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 2005, 17:338-344.
27. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004, 304:1014-1018.
28. Doyle S.E., O'Connell R.M., Miranda G.A., Vaidya S.A., Chow E.K., Liu P.T., Suzuki S., Suzuki N., Modlin R.L., Yeh W.C., Lane T.F., Cheng G. Toll-like receptors induce a phagocytic gene program through p38. J. Exp. Med. 2004, 199:81-90.
29. Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.
30. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., Luthringer D., Xu X.P., Rajavashisth T.B., Yano J., Kaul S., Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
31. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161.
32. Mullick A.E., Tobias P.S., Curtiss L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 2005, 115:3149-3156.
33. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., Akira S., Rajavashisth T.B., Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10679-10684.
34. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002, 23:509-512.
35. Wagner H. Endogenous TLR ligands and autoimmunity. Adv. Immunol. 2006, 91:159-173.
36. Björkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr. Opin. Lipidol. 2006, 17:527-533.
37. Yang X., Coriolan D., Murthy V., Schultz K., Golenbock D.T., Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1069-H1076.
38. Yang X., Coriolan D., Schultz K., Golenbock D.T., Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2308-2314.
39. Jimenez R., Belcher E., Sriskandan S., Lucas R., McMaster S., Vojnovic I., Warner T.D., Mitchell J.A. Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4637-4642.
40. Yang X., Murthy V., Schultz K., Tatro J.B., Fitzgerald K.A., Beasley D. Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2334-H2343.
41. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
42. Li X., Massa P.E., Hanidu A., Peet G.W., Aro P., Savitt A., Mische S., Li J., Marcu K.B. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J. Biol. Chem. 2002, 277:45129-45140.
43. LaDu M.J., Shah J.A., Reardon C.A., Getz G.S., Bu G., Hu J., Guo L., van Eldik L.J. Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J. Biol. Chem. 2000, 275:33974-33980.
44. Saura J., Petegnief V., Wu X., Liang Y., Paul S.M. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J. Neurochem. 2003, 85:1455-1467.
45. Li M., Carpio D.F., Zheng Y., Bruzzo P., Singh V., Ouaaz F., Medzhitov R.M., Beg A.A. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 2001, 166:7128-7135.
46. Urban J., Parczyk K., Leutz A., Kayne M., Kondor-Koch C. Constitutive apical secretion of an 80-kD sulfated glycoprotein complex in the polarized epithelial Madin-Darby canine kidney cell line. J. Cell Biol. 1987, 105:2735-2743.
47. Sivori S., Falco M., Della Chiesa M., Carlomagno S., Vitale M., Moretta L., Moretta A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10116-10121.
48. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643.
49. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., Randall R.E. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17264-17269.
50. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
51. de Bouteiller O., Merck E., Hasan U.A., Hubac S., Benguigui B., Trinchieri G., Bates E.E., Caux C. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 2005, 280:38133-38145.
52. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279:12542-12550.
53. Brentano F., Schorr O., Gay R.E., Gay S., Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005, 52:2656-2665.
54. Lee H., Jo E.K., Choi S.Y., Oh S.B., Park K., Kim J.S., Lee S.J. Necrotic neuronal cells induce inflammatory Schwann cell activation via TLR2 and TLR3: implication in Wallerian degeneration. Biochem. Biophys. Res. Commun. 2006, 350:742-747.
55. Hardardottir I., Sipe J., Moser A.H., Fielding C.J., Feingold K.R., Grünfeld C. LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim. Biophys. Acta 1997, 1344:210-220.
56. Hardardottir I., Kunitake S.T., Moser A.H., Doerrler W.T., Rapp J.H., Grünfeld C., Feingold K.R. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J. Clin. Invest. 1994, 94:1304-1309.
57. Cavassani K.A., Ishii M., Wen H., Schaller M.A., Lincoln P.M., Lukacs N.W., Hogaboam C.M., Kunkel S.L. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 2008, 205:2609-2621.
58. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 1998, 2:275-281.
59. Yerbury J.J., Stewart E.M., Wyatt A.R., Wilson M.R. Quality control of protein folding in extracellular space. EMBO Rep. 2005, 6:1131-1136.
60. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J. Biol. Chem. 1997, 272:18644-18649.
61. Urbich C., Fritzenwanger M., Zeiher A.M., Dimmeler S. Laminar shear stress upregulates the complement-inhibitory protein clusterin. A novel potent defense mechanism against complement-induced endothelial cell activation. Circulation 2000, 101:352-355.
62. Schwarz M., Spath L., Lux C.A., Paprotka K., Torzewski M., Dersch K., Koch-Brandt C., Husmann M., Bhakdi S. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb. Haemost. 2008, 100:110-118.
63. Kim H.J., Yoo E.K., Kim J.Y., Choi Y.K., Lee H.J., Kim J.K., Jeoung N.H., Lee K.U., Park I.S., Min B.H., Park K.G., Lee C.H., Aronow B.J., Sata M., Lee I.K. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1558-1564.
64. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Wagner A.C., Hama S., Hough G., Bachini E., Garber D.W., Mishra V.K., Palgunachari M.N., Fogelman A.M. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1932-1937.
65. Essabbani A., Margottin-Goguet F., Chiocchia G. Identification of clusterin domain involved in NF-kappaB pathway regulation. J. Biol. Chem. 2010, 285:4273-4277.
66. Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A., Klomp L.W., Nelson C.C., Rennie P.S., Gleave M.E. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol. Cancer Res. 2010, 8:119-130.
67. Kawamura A., Baitsch D., Telgmann R., Feuerborn R., Weissen-Plenz G., Hagedorn C., Saku K., Brand-Herrmann S.M., von Eckardstein A., Assmann G., Nofer J.R. Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1610-1617.